Главная › Рак (все виды) › Массачусетс › Boston
Клинические исследования Рак (все виды) в городе Boston, MA
86 исследований по теме Рак (все виды) ищут участников в центрах в городе Boston и поблизости (в радиусе около 30 миль). Откройте исследование, чтобы узнать критерии участия и контакты исследовательской группы.
Официальный текст исследования (на английском)
Ищете участников для исследования? Разместите его вверху страницы — $99 на 30 дней →
Distance-Based Exercise to Preserve Function and Prevent Disability
Набор участников
- Dana-Farber Cancer Institute, Boston
A Study of ASP3082 in Adults With Advanced Solid Tumors
Набор участниковФаза 1
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Набор участниковФаза 1
- Beth Israel Deaconess Medical Center - Research, Boston
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Набор участниковНаблюдательное исследование
- Mass General Brigham, Boston
- Brigham and Women's Hospital, Boston
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Набор участниковФаза 1
- Massachusetts General Hospital, Boston
A Study of PHN-012 in Patients With Advanced Solid Tumors
Набор участниковФаза 1
- PHN-012-001 Site, Boston
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Набор участниковФаза 3
- Investigative Site, Boston
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Набор участниковФаза 1/2
- Dana Farber Cancer Center ( Site 4013), Boston
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Набор участниковФаза 3
- Dana Farber/Harvard Cancer Center, Boston
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
Набор участников
- Massachusetts General Hospital, Boston
Pan Tumor Rollover Study
Набор участниковФаза 2
- Dana_Farber Cancer Institute (DFCI), Boston
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Набор участниковФаза 3
- Beth Israel Deaconess Medical Center ( Site 0107), Boston
- Dana-Farber Cancer Institute ( Site 0105), Boston
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Набор участниковФаза 3
- Dana-Farber Cancer Institute /ID# 279690, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Набор участниковФаза 1/2
- Dana Farber Cancer Institute, Boston
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Набор участниковФаза 2/3
- Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Набор участниковФаза 1/2
- Dana-Farber Cancer Institute ( Site 3013), Boston
Statins to Prevent Cancer Associated Blood Clots
Набор участниковФаза 4
- Beth Isreal Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Proof-of-Concept Testing of the Cardiovascular Health Equity Through Food (CHEF) Intervention in Childhood Cancer Survivors
Набор участников
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
ACTIVATE: AI-driven Clinical-trial Trial-Information and Viability Assessment Tool for EHRs
Набор участников
- Dana-Farber Cancer Institute, Boston
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Набор участниковФаза 2
- Dana Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Набор участниковФаза 2
- Dana-Farber Cancer Institute, Boston
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Набор участниковФаза 1/2
- Dana-Farber Cancer Institute /ID# 271846, Boston
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Набор участниковФаза 1/2
- Research Site, Boston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Набор участниковФаза 1
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Набор участниковФаза 1/2
- Dana-Farber Cancer Institute, Boston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Набор участниковФаза 3
- Boston Medical Center, Boston
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Набор участниковНаблюдательное исследование
- Dana Farber Cancer Institute, Boston
Lurbinectedin in FET-Fused Tumors
Набор участниковФаза 1/2
- Dana-Farber Cancer Institute, Boston
Prostate Active Surveillance Study
Набор участниковНаблюдательное исследование
- Beth Israel Deaconess Medical Center/Harvard Medical School, Boston
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Набор участниковФаза 1
- Massachusetts General Hospital (MG), Boston
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Набор участниковФаза 1
- Massachusetts General Hospital, Boston
BRIDGE-SIC Efficacy Trial
Набор участников
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Project: Every Child for Younger Patients With Cancer
Набор участниковНаблюдательное исследование
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Abatacept in Immune Checkpoint Inhibitor Myocarditis
Набор участниковФаза 3
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Boston Medical Center, Boston
- и еще 1
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Набор участниковФаза 1/2
- Massachusetts General Hospital, Boston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Набор участниковФаза 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
Набор участниковФаза 1
- Beth Israel Deaconess Medical Center, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Набор участниковФаза 1/2
- Massachusetts General Hospital Cancer Center, Boston
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Набор участниковФаза 1
- Dana-Farber Cancer Institute, Boston
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Набор участниковФаза 2
- Dana-Farber Cancer Institute, Boston
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
Набор участниковФаза 1Приглашаются здоровые добровольцы
- Boston Medical Center, Boston
- Massachusetts General Hospital (MGH), Charlestown · 1 миль отсюда
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Набор участниковФаза 1
- Brigham and Women's Hospital, Boston
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Набор участниковФаза 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Набор участниковФаза 2
- Massachusetts General Hospital /ID# 273608, Boston
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Набор участниковФаза 1
- Dana-Farber Cancer Institute, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Набор участниковФаза 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
The STOP-MED CTRCD Trial
Набор участниковФаза 4
- Brigham and Women's Hospital, Boston
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Набор участниковФаза 1/2
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
Набор участниковФаза 1
- GSK Investigational Site, Boston
- GSK Investigational Site, Boston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Набор участниковФаза 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Childhood Cancer Survivor Study
Набор участниковНаблюдательное исследованиеПриглашаются здоровые добровольцы
- Dana-Farber Cancer Institute, Boston
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Набор участников
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Набор участниковФаза 1
- Research Site, Boston
- Research Site, Boston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Набор участниковФаза 1
- Beth Israel Deaconess Medical Center /ID# 252009, Boston
- Dana-Farber Cancer Institute /ID# 249642, Boston
Multisite Implementation of COMPRENDO
Набор участниковПриглашаются здоровые добровольцы
- Dana Farber Cancer Institute/Boston Children's Hospital, Boston
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Набор участниковФаза 1
- Mass General Brigham Cancer Institute, Boston
- Dana Farber Cancer Institute, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Набор участниковФаза 1/2
- Massachusetts General Hospital,, Boston
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
Набор участниковФаза 1
- GSK Investigational Site, Boston
Video Inspired Discussions About Ethical Outcomes in Pediatrics
Набор участников
- Dana Farber Cancer Institute, Boston
On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety
Набор участниковУказана оплата для участников
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Набор участниковФаза 1/2
- Massachusetts General Hospital, Boston
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
Набор участниковФаза 2
- Dana Farber Cancer Institute, Boston
Intraoperative Tumor Margin Identification With ICG Dye Imaging
Набор участниковФаза 2
- Massachusetts General Hospital, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Набор участниковФаза 1/2
- Dana Farber Cancer Institute, Boston
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Набор участниковФаза 1
- Massachusetts General Hospital, Boston
Suprachoroidal Administration in Subjects With Metastases to the Choroid
Набор участниковФаза 2
- Massachusetts Eye and Ear, Boston
Supportive Care Intervention for Outpatient Stem Cell Transplant Patients
Набор участников
- Dana-Farber Cancer Institute, Boston
Positron Emission Tomography (PET) Imaging of Thrombosis
Набор участниковФаза 1Приглашаются здоровые добровольцы
- Massachusetts General Hospital, Boston
Primary Tumor Research and Outcomes Network
Набор участниковНаблюдательное исследование
- Massachusetts General Hospital, Boston
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Набор участниковФаза 1/2
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Набор участников
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
PediRISE Feasibility
Набор участников
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Набор участниковФаза 2
- Dana-Farber Cancer Institute /ID# 230061, Boston
A Dyadic Intervention for Young Adult Patients With Cancer and Their Partner Caregivers
Набор участников
- Massachusetts General Hospital Cancer Center, Boston
A Study of YL242 in Subjects With Advanced Solid Tumors
Набор участниковФаза 1/2
- US-204, Boston
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
Набор участниковНаблюдательное исследование
- Boston Children's Hospital, Boston
Eliminating Barriers to Colorectal Cancer Screening Using Rapid Cycle Testing: A Pilot Study
Набор участниковПриглашаются здоровые добровольцы
- Codman Square Health Center, Boston
- East Boston Neighborhood Health Center, East Boston · 2 миль отсюда
Childhood Cancer Predisposition Study (CCPS)
Набор участниковНаблюдательное исследование
- Dana Farber Cancer Institute, Boston
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
Набор участников
- Massachusetts General Hospital Cancer Center, Boston
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
Набор участниковНаблюдательное исследование
- Massachusetts General Hospital, Boston
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
Набор участников
- Harvard School of Medicine/Massachusetts General Hospital (MGH), Boston
Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository
Набор участниковФаза 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs
Набор участниковПриглашаются здоровые добровольцы
- Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Набор участниковФаза 1/2
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Набор участниковФаза 1/2
- Massachusetts General Hospital, Boston
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
Набор участниковФаза 3
- Massachusetts General Hospital, Boston
Исследования Рак (все виды) в других городах
- Houston, TX121 исследование
- New York City, NY110 исследований
- Los Angeles, CA73 исследований
- Nashville, TN65 исследований
- Philadelphia, PA59 исследований
- Durham, NC58 исследований
- Washington, DC58 исследований
- Chicago, IL51 исследование
- Seattle, WA49 исследований
- Atlanta, GA49 исследований
- Arlington, VA48 исследований
- St. Louis, MO46 исследований
Другие исследования в городе Boston
- Рак молочной железы111 исследований
- Немелкоклеточный рак легкого90 исследований
- Колоректальный рак63 исследований
- Метастатический рак63 исследований
- Рак легких62 исследований
- Рак яичников61 исследование
- Рак простаты59 исследований
- Депрессия52 исследований
- Рак эндометрия50 исследований
- Сердечная недостаточность44 исследований
- Острый миелоидный лейкоз44 исследований
- Рак поджелудочной железы43 исследований
Источник: ClinicalTrials.gov, данные получены 5 окт. 2026 г.. Каждая исследование устанавливает свои критерии участия; решение о включении принимает исследовательская группа.